These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Antibodies as specific tumor therapy agents. Wishful thinking or reality?]. Gramatzki M; Valerius T Internist (Berl); 1997 Nov; 38(11):1055-62. PubMed ID: 9453954 [No Abstract] [Full Text] [Related]
7. The EGF receptor system as a target for antitumor therapy. Ennis BW; Lippman ME; Dickson RB Cancer Invest; 1991; 9(5):553-62. PubMed ID: 1933488 [TBL] [Abstract][Full Text] [Related]
8. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Lorimer IA; Keppler-Hafkemeyer A; Beers RA; Pegram CN; Bigner DD; Pastan I Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14815-20. PubMed ID: 8962138 [TBL] [Abstract][Full Text] [Related]
9. Growth factor receptor monoclonal antibodies and cancer immunotherapy. Sato GH; Sato JD J Natl Cancer Inst; 1989 Nov; 81(21):1600-1. PubMed ID: 2795686 [No Abstract] [Full Text] [Related]
10. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
11. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. Wels W; Groner B; Hynes NE Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001 [No Abstract] [Full Text] [Related]
12. [Immunotherapy of malignant growth]. Tobiasch V Lebensversicher Med; 1986 Sep; 38(5):133-9. PubMed ID: 2877376 [No Abstract] [Full Text] [Related]
13. [Use of monoclonal antibodies in the immunotherapy of neoplasms]. Robak T Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121 [No Abstract] [Full Text] [Related]
14. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Chandramohan V; Mitchell DA; Johnson LA; Sampson JH; Bigner DD Future Oncol; 2013 Jul; 9(7):977-90. PubMed ID: 23837761 [TBL] [Abstract][Full Text] [Related]
15. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606 [TBL] [Abstract][Full Text] [Related]
16. Antibody conjugates for the treatment of cancer. Pietersz GA; McKenzie IF Immunol Rev; 1992 Oct; 129():57-80. PubMed ID: 1464422 [No Abstract] [Full Text] [Related]
17. Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells. Bodey B Expert Opin Biol Ther; 2001 Jul; 1(4):603-17. PubMed ID: 11727497 [TBL] [Abstract][Full Text] [Related]
18. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts. Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526 [TBL] [Abstract][Full Text] [Related]
19. Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. Peipp M; Dechant M; Valerius T MAbs; 2009; 1(6):590-9. PubMed ID: 20068398 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with antibodies to the EGF receptor. Dean C; Modjtahedi H; Eccles S; Box G; Styles J Int J Cancer Suppl; 1994; 8():103-7. PubMed ID: 8194887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]